Filetype
Study objectives: A method for medication reconciliation that reduces medication errors and healthcare contacts when a patient is discharged from hospital, LIMM-DI (Lund integrated medicines management-discharge information) had been previously developed by the authors. LIMM-DI is structured information written for the patient and sent to the next caregiver. In this study, the use (implementation
Hard-to-heal wounds are a growing human and financial concern, constituting approximately 1–3% of the healthcare budget. Wound care is not a medical specialty and is often not prioritized within healthcare. A large portion of the cost and suffering caused by wounds has the potential to be mediated through improved knowledge and effectivised workflows. One potential way to achieve this is through t
Despite the lack of scientific evidence for the effectiveness of Flexible Assertive Community Treatment (Flexible ACT), the model disseminates rapidly in the mental health services in a number of countries. This is in contrast to many evidence-based practices that often face comprehensive implementation barriers. Knowledge is needed on the dissemination of Flexible ACT to understand the relative s
P>Many ecological, physical and geographical processes affected by climate in the natural environment are scale-dependent: determining surface-air-temperature distribution at a scale of tens to hundreds of metres can facilitate such research, which is currently hampered by the relative dearth of meteorological stations and complex surface temperature characteristics, particularly in mountain areas
Patients with cystic fibrosis (CF) colonized with Pseudomonas aeruginosa (P. aeruginosa) have worse prognosis compared with patients who are not. BPI-ANCA is an anti-neutrophil cytoplasmic antibody against BPI (bactericidal/permeability increasing protein) correlating with P. aeruginosa colonization and adverse long time prognosis. Whether it provides additional information as compared to standard
Objectives: Evidence regarding the efficacy and effectiveness of certolizumab pegol (CZP) in rheumatoid arthritis (RA) patients who have failed to respond to treatment with a tumour necrosis factor inhibitor (TNFi) is limited. The aim of this study was to describe the effectiveness and survival-on-drug of CZP in a real-life setting, both in TNFi-naive patients and in patients who had previously fa
